Klaus Elenius focuses on Cancer research, Cell biology, ERBB4, Gene isoform and Epidermal growth factor. His studies in Cancer research integrate themes in fields like Cancer, Breast cancer, Trastuzumab, ErbB and Gefitinib. His Cancer study incorporates themes from Stomach, Chromogenic in situ hybridization and CISH.
ERBB4 is a primary field of his research addressed under Signal transduction. His Epidermal growth factor research is multidisciplinary, incorporating elements of Molecular biology and Tyrosine phosphorylation. Klaus Elenius interconnects Receptor tyrosine kinase and Binding site in the investigation of issues within Tyrosine phosphorylation.
Klaus Elenius spends much of his time researching Cancer research, Receptor tyrosine kinase, Cell biology, ERBB4 and ErbB. The concepts of his Cancer research study are interwoven with issues in Cancer, Breast cancer, ERBB3, Epidermal growth factor receptor and Cell growth. His study in Cancer is interdisciplinary in nature, drawing from both Mutation and Chromogenic in situ hybridization.
His Receptor tyrosine kinase research incorporates themes from Molecular biology and Kinase activity. His research in Cell biology intersects with topics in Syndecan 1, Endocrinology, Internal medicine, Angiogenesis and Ectodomain. His ERBB4 study integrates concerns from other disciplines, such as Tyrosine kinase, Neuregulin and Gene isoform.
His primary areas of study are Receptor tyrosine kinase, Cell biology, Cancer research, ErbB and Epidermal growth factor receptor. His work deals with themes such as Gene expression, Downregulation and upregulation, Afatinib, Somatic evolution in cancer and Guanine Nucleotide Exchange Factor VAV3, which intersect with Receptor tyrosine kinase. His studies deal with areas such as Muscle hypertrophy and VEGF receptors as well as Cell biology.
The study incorporates disciplines such as Blot, ROR1, Carcinoma, Phosphorylation and Extracellular matrix in addition to Cancer research. In his study, Ubiquitin ligase, Cancer and In situ hybridization is inextricably linked to Cell culture, which falls within the broad field of ErbB. His Mutation research is multidisciplinary, incorporating perspectives in Jaw neoplasm and Signal transduction.
Cell biology, Receptor tyrosine kinase, Tyrosine kinase, Mutation and Cancer research are his primary areas of study. Klaus Elenius has researched Cell biology in several fields, including Muscle hypertrophy, Receptor, Paracrine signalling and VEGF receptors. His Receptor tyrosine kinase research incorporates elements of Regulated Intramembrane Proteolysis, Ectodomain, Proteasome, Gamma secretase and Transmembrane domain.
He frequently studies issues relating to Cleavage and Tyrosine kinase. His Mutation study combines topics from a wide range of disciplines, such as EGFR Exon 19 Deletion Mutation, Epidermal growth factor receptor, Kinase, Kinase activity and Protein kinase domain. He combines subjects such as Cetuximab, EGFR Antibody, Chemotherapy, Oxaliplatin and KRAS with his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M. Tanner;M. Hollmén;T. T. Junttila;A. I. Kapanen.
Annals of Oncology (2005)
ACTIVATION OF HER4 BY HEPARIN-BINDING EGF-LIKE GROWTH FACTOR STIMULATES CHEMOTAXIS BUT NOT PROLIFERATION
Klaus Elenius;Subroto Paul;Genève Allison;Jilin Sun.
The EMBO Journal (1997)
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
Kaisa Erjala;Maria Sundvall;Teemu T. Junttila;Na Zhang.
Clinical Cancer Research (2006)
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
Minna Tanner;Anita I Kapanen;Teemu Junttila;Olayinka Raheem.
Molecular Cancer Therapeutics (2004)
Induced expression of syndecan in healing wounds.
K Elenius;S Vainio;M Laato;M Salmivirta.
Journal of Cell Biology (1991)
Syndecan from embryonic tooth mesenchyme binds tenascin.
M Salmivirta;K Elenius;S Vainio;U Hofer.
Journal of Biological Chemistry (1991)
A Novel Juxtamembrane Domain Isoform of HER4/ErbB4 ISOFORM-SPECIFIC TISSUE DISTRIBUTION AND DIFFERENTIAL PROCESSING IN RESPONSE TO PHORBOL ESTER
Klaus Elenius;Gabriel Corfas;Subroto Paul;Caroline J. Choi.
Journal of Biological Chemistry (1997)
High frequency of BRAF V600E mutations in ameloblastoma
Kari J Kurppa;Javier Catón;Peter R Morgan;Ari Ristimäki.
The Journal of Pathology (2014)
A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.
Varpu Kainulainen;Maria Sundvall;Jorma A. Määttä;Eric Santiestevan.
Journal of Biological Chemistry (2000)
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
Teemu T. Junttila;Maria Sundvall;Mikael Lundin;Johan Lundin.
Cancer Research (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: